tirzepatide china approval With approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs China Clears Eli Lilly's Weight

If the Dopamine-like medication is successful in both reducing the prolactin level to normal and causing the tumor to become invisible on MRI, they can be slowly stopped after a minimum of two years of treatment

(Caveat: A new analysis from Cleveland Clinic, involving nearly 8,000 patients, suggests that stopping drugs like semaglutide and tirzepatide (GLP1 drugs) does not typically result in major weight regain in real-world settings

The Epic study based at Oxford follows about 2,000 people

Venous blood samples were obtained before and after 8 weeks

Could GLP-1s follow similar approval trajectory and commercial growth